This position paper describes the concerns of some Consortium members at the apparent policy differences emerging between different United Nations agencies, and individual member states, in the run up to the annual meeting of the UN agency responsible for oversight of the global drug control system. This meeting, held in Vienna in March, runs the risk of approving positions on Harm Reduction and Afghanistan that are at odds with the available evidence of what works in reducing drug problems.
- FAST-TRACK or OFF TRACK? How insufficient funding for key populations jeopardises ending AIDS by 2030
- Women and barriers to harm reduction services: A literature review and initial findings from a qualitative study in Barcelona, Spain
- Clean Start: Creating second chances for women and girls in Kenya
- Addressing the syndemic of HIV, hepatitis C, overdose, and COVID-19 among people who use drugs: the potential roles for decriminalization and safe supply
- How diverse is Canada’s legal cannabis industry? Examining race and gender of its executives and directors
- Coca and Its medical applications: Prospects, obstacles and lessons learned
- Funding what is possible. Robert Carr fund annual report 2019.
- The impact of arrest and seizure on drug crime and harms: A systematic review
- Addressing stigma and discrimination in the COVID-19 response